Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

M. Wang, W. Jurczak, M. Trneny, D. Belada, T. Wrobel, N. Ghosh, MM. Keating, T. van Meerten, RF. Alvarez, G. von Keudell, C. Thieblemont, F. Peyrade, M. Andre, M. Hoffmann, E. Szafer-Glusman, J. Lin, JP. Dean, JK. Neuenburg, CS. Tam

. 2025 ; 26 (2) : 200-213. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, klinické zkoušky, fáze III, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009996
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 39914418
DOI 10.1016/s1470-2045(24)00682-x
Knihovny.cz E-zdroje

BACKGROUND: The combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety of ibrutinib-venetoclax compared with ibrutinib-placebo in patients with relapsed or refractory MCL. METHODS: SYMPATICO is a multicentre, randomised, double-blind, placebo-controlled, phase 3 study performed at 84 hospitals in Europe, North America, and Asia-Pacific. Eligible patients were adults (aged ≥18 years) with pathologically confirmed relapsed or refractory MCL after one to five previous lines of therapy and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients were randomly assigned (1:1) to receive oral ibrutinib 560 mg once daily concurrently with oral venetoclax (5-week ramp-up to 400 mg once daily) or placebo for 2 years, then single-agent ibrutinib 560 mg once daily until disease progression or unacceptable toxicity. Randomisation and treatment assignment occurred via interactive response technology using a stratified permuted block scheme (block sizes of 2 and 4) with stratification by ECOG performance status, previous lines of therapy, and tumour lysis syndrome risk category. Patients and investigators were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03112174, and is closed to enrolment. FINDINGS: Between April 26, 2018, and Aug 28, 2019, 267 patients were enrolled and randomly assigned; 134 to the ibrutinib-venetoclax group and 133 to the ibrutinib-placebo group. 211 (79%) of 267 patients were male and 56 (21%) were female. With a median follow-up of 51·2 months (IQR 48·2-55·3), median progression-free survival was 31·9 months (95% CI 22·8-47·0) in the ibrutinib-venetoclax group and 22·1 months (16·5-29·5) in the ibrutinib-placebo group (hazard ratio 0·65 [95% CI 0·47-0·88]; p=0·0052). The most common grade 3-4 adverse events were neutropenia (42 [31%] of 134 patients in the ibrutinib-venetoclax group vs 14 [11%] of 132 patients in the ibrutinib-placebo group), thrombocytopenia (17 [13%] vs ten [8%]), and pneumonia (16 [12%] vs 14 [11%]). Serious adverse events occurred in 81 (60%) of 134 patients in the ibrutinib-venetoclax group and in 79 (60%) of 132 patients in the ibrutinib-placebo group. Treatment-related deaths occurred in three (2%) of 134 patients in the ibrutinib-venetoclax group (n=1 COVID-19 infection, n=1 cardiac arrest, and n=1 respiratory failure) and in two (2%) of 132 patients in the ibrutinib-placebo group (n=1 cardiac failure and n=1 COVID-19-related pneumonia). INTERPRETATION: The combination of ibrutinib-venetoclax significantly improved progression-free survival compared with ibrutinib-placebo in patients with relapsed or refractory MCL. The safety profile was consistent with known safety profiles of the individual drugs. These findings suggest a positive benefit-risk profile for ibrutinib-venetoclax treatment. FUNDING: Pharmacyclics (an AbbVie Company) and Janssen Research and Development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009996
003      
CZ-PrNML
005      
20250429135108.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(24)00682-X $2 doi
035    __
$a (PubMed)39914418
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Wang, Michael $u Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: miwang@mdanderson.org
245    10
$a Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study / $c M. Wang, W. Jurczak, M. Trneny, D. Belada, T. Wrobel, N. Ghosh, MM. Keating, T. van Meerten, RF. Alvarez, G. von Keudell, C. Thieblemont, F. Peyrade, M. Andre, M. Hoffmann, E. Szafer-Glusman, J. Lin, JP. Dean, JK. Neuenburg, CS. Tam
520    9_
$a BACKGROUND: The combination of ibrutinib and venetoclax leverages complementary mechanisms of action and has shown promising clinical activity in mantle cell lymphoma (MCL). This study evaluated the efficacy and safety of ibrutinib-venetoclax compared with ibrutinib-placebo in patients with relapsed or refractory MCL. METHODS: SYMPATICO is a multicentre, randomised, double-blind, placebo-controlled, phase 3 study performed at 84 hospitals in Europe, North America, and Asia-Pacific. Eligible patients were adults (aged ≥18 years) with pathologically confirmed relapsed or refractory MCL after one to five previous lines of therapy and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients were randomly assigned (1:1) to receive oral ibrutinib 560 mg once daily concurrently with oral venetoclax (5-week ramp-up to 400 mg once daily) or placebo for 2 years, then single-agent ibrutinib 560 mg once daily until disease progression or unacceptable toxicity. Randomisation and treatment assignment occurred via interactive response technology using a stratified permuted block scheme (block sizes of 2 and 4) with stratification by ECOG performance status, previous lines of therapy, and tumour lysis syndrome risk category. Patients and investigators were masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03112174, and is closed to enrolment. FINDINGS: Between April 26, 2018, and Aug 28, 2019, 267 patients were enrolled and randomly assigned; 134 to the ibrutinib-venetoclax group and 133 to the ibrutinib-placebo group. 211 (79%) of 267 patients were male and 56 (21%) were female. With a median follow-up of 51·2 months (IQR 48·2-55·3), median progression-free survival was 31·9 months (95% CI 22·8-47·0) in the ibrutinib-venetoclax group and 22·1 months (16·5-29·5) in the ibrutinib-placebo group (hazard ratio 0·65 [95% CI 0·47-0·88]; p=0·0052). The most common grade 3-4 adverse events were neutropenia (42 [31%] of 134 patients in the ibrutinib-venetoclax group vs 14 [11%] of 132 patients in the ibrutinib-placebo group), thrombocytopenia (17 [13%] vs ten [8%]), and pneumonia (16 [12%] vs 14 [11%]). Serious adverse events occurred in 81 (60%) of 134 patients in the ibrutinib-venetoclax group and in 79 (60%) of 132 patients in the ibrutinib-placebo group. Treatment-related deaths occurred in three (2%) of 134 patients in the ibrutinib-venetoclax group (n=1 COVID-19 infection, n=1 cardiac arrest, and n=1 respiratory failure) and in two (2%) of 132 patients in the ibrutinib-placebo group (n=1 cardiac failure and n=1 COVID-19-related pneumonia). INTERPRETATION: The combination of ibrutinib-venetoclax significantly improved progression-free survival compared with ibrutinib-placebo in patients with relapsed or refractory MCL. The safety profile was consistent with known safety profiles of the individual drugs. These findings suggest a positive benefit-risk profile for ibrutinib-venetoclax treatment. FUNDING: Pharmacyclics (an AbbVie Company) and Janssen Research and Development.
650    _2
$a lidé $7 D006801
650    12
$a adenin $x analogy a deriváty $7 D000225
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D019086
650    12
$a sulfonamidy $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D013449
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a lymfom z plášťových buněk $x farmakoterapie $x patologie $x mortalita $7 D020522
650    12
$a piperidiny $x aplikace a dávkování $7 D010880
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Jurczak, Wojciech $u Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland
700    1_
$a Trneny, Marek $u General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Wrobel, Tomasz $u Wrocław Medical University, Wrocław, Poland
700    1_
$a Ghosh, Nilanjan $u Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA
700    1_
$a Keating, Mary-Margaret $u Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
700    1_
$a van Meerten, Tom $u Universitair Medisch Centrum Groningen, Groningen, Netherlands
700    1_
$a Alvarez, Ruben Fernandez $u Hospital Universitario de Cabueñes, Asturias, Spain
700    1_
$a von Keudell, Gottfried $u Beth Israel Deaconess Medical Center, Boston, MA, USA
700    1_
$a Thieblemont, Catherine $u Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France
700    1_
$a Peyrade, Frederic $u Centre Antoine Lacassagne, Nice, France
700    1_
$a Andre, Marc $u CHU UCL Namur Mont-Godinne, Yvoir, Belgium
700    1_
$a Hoffmann, Marc $u University of Kansas Cancer Center, Westwood, KS, USA
700    1_
$a Szafer-Glusman, Edith $u AbbVie, North Chicago, IL, USA
700    1_
$a Lin, Jennifer $u AbbVie, North Chicago, IL, USA
700    1_
$a Dean, James P $u AbbVie, North Chicago, IL, USA
700    1_
$a Neuenburg, Jutta K $u AbbVie, North Chicago, IL, USA
700    1_
$a Tam, Constantine S $u Peter MacCallum Cancer Centre, Alfred Health and Monash University, Melbourne, VIC, Australia
773    0_
$w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 26, č. 2 (2025), s. 200-213
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39914418 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135104 $b ABA008
999    __
$a ok $b bmc $g 2311394 $s 1247077
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 2 $d 200-213 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol $x MED00011558
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace